Schrodinger (NASDAQ:SDGR – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.6665) per share and revenue of $47.67 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.
Schrodinger (NASDAQ:SDGR – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.49. Schrodinger had a negative net margin of 20.98% and a negative return on equity of 16.37%. The company had revenue of $58.89 million during the quarter, compared to the consensus estimate of $47.19 million. During the same period in the previous year, the firm earned ($0.65) earnings per share. Schrodinger’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, analysts expect Schrodinger to post ($1.50) EPS for the current fiscal year and ($1.10) EPS for the next fiscal year.
Schrodinger Price Performance
Schrodinger stock opened at $27.14 on Monday. The firm has a fifty day moving average of $24.96 and a 200-day moving average of $16.81. Schrodinger has a 52-week low of $10.94 and a 52-week high of $33.78. The firm has a market capitalization of $2.00 billion, a P/E ratio of -36.68 and a beta of 1.69.
Insider Transactions at Schrodinger
In other Schrodinger news, insider Karen Akinsanya sold 31,599 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $29.37, for a total value of $928,062.63. Following the completion of the transaction, the insider directly owned 69,956 shares of the company’s stock, valued at $2,054,607.72. This represents a 31.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.10% of the stock is owned by company insiders.
Analyst Ratings Changes
Several brokerages recently issued reports on SDGR. Weiss Ratings upgraded Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. UBS Group boosted their price objective on Schrodinger from $19.00 to $21.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 20th. KeyCorp upped their target price on Schrodinger from $20.00 to $32.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Zacks Research upgraded Schrodinger from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 5th. Finally, BMO Capital Markets raised their target price on Schrodinger from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.83.
View Our Latest Research Report on Schrodinger
Schrodinger Company Profile
Schrödinger, Inc develops computational software and services designed to support pharmaceutical, biotechnology and materials research. Its platform uses physics-based modeling, machine learning and other computational methods to help scientists analyze molecular interactions, design compounds and prioritize candidates for experimental testing.
The company’s software offerings include tools for molecular modeling, quantum chemistry, molecular dynamics, virtual screening, property prediction and free-energy calculations.
See Also
- Five stocks we like better than Schrodinger
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.
